---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-004747"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2025-01-21T23:59:59+00:00"
generated_at: "2026-05-27T21:58:12.929894+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "low"
source: SEC EDGAR
---

# Cara Therapeutics files investor presentation for proposed merger with Tvardi

## Summary
- Furnishes investor presentation (Exhibit 99.1) for post-combination company with Tvardi, a STAT3-targeted fibrosis biopharma.
- Merger announced Dec 17, 2024; pending regulatory and shareholder approvals; S-4 filed with preliminary proxy/prospectus.
- Presentation is being shared with potential investors; no new financial terms or deal value disclosed in filing.
- Forward-looking statements reference efforts to regain Nasdaq compliance on stockholders' equity requirement.

## SEC filing metadata
- accession: 0001104659-25-004747
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2025-01-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465925004747/0001104659-25-004747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465925004747/tm253758d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-004747
- JSON: https://secwatch.observer/filing/0001104659-25-004747.json
- Plain text: https://secwatch.observer/filing/0001104659-25-004747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.